Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Reduced erythrocyte lifespan measured by chromium-51 in patients with type 2 diabetes undergoing long-term hemodialysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Intravascular volumes evaluated by a carbon monoxide rebreathing method in patients undergoing chronic hemodialysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased risk of Staphylococcus aureus bacteremia in hemodialysis-A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treatment of a soft tissue calcification in a patient receiving peritoneal dialysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Kidney function and the prognostic value of myocardial performance index

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Research output: Contribution to journalReviewpeer-review

  3. Multiple endocrine neoplasia type 2: A reveiw

    Research output: Contribution to journalReviewpeer-review

View graph of relations

INTRODUCTION: A reduced erythrocyte lifespan potentially explains the low hemoglobin A1c values found in hemodialysis patients. However, data supporting this notion in patients with type 2 diabetes is unclear. We evaluated the erythrocyte lifespan in patients with type 2 diabetes undergoing long-term hemodialysis and investigated potential predictors of erythrocyte lifespan.

METHODS: Long-term hemodialysis patients with type 2 diabetes and type 2 diabetes patients without nephropathy (estimated glomerular filtration rate > 60 mL/min/1.73 m2 ) were included. The erythrocyte lifespan was measured using chromium-51 (51 Cr)-labeled erythrocytes. Blood radiotracer activity was measured six to nine times over a period of 3-5 weeks to determine the erythrocyte lifespan of each patient. Biochemical markers were obtained five times over 16 weeks and associated with the erythrocyte lifespan.

FINDINGS: Type 2 diabetes patients undergoing hemodialysis (N = 13) had a significantly shorter median erythrocyte lifespan of 49.7 (interquartile range [IQR] = 44.1-58.6) days compared with 64.2 (IQR = 62.6-83.5) days in the control group (N = 10) (P ˂ 0.001) with a difference between medians of 14.5 (95% confidence interval = 8.1-38.8) days. In the hemodialysis group, no association could be detected between the erythrocyte lifespan and markers of hemolysis, level of inflammation, or urea.

DISCUSSION: A reduced erythrocyte lifespan was detected in type 2 diabetes patients undergoing long-term hemodialysis. This may contribute to the reduced hemoglobin A1c values observed in the type 2 diabetic hemodialysis population. An association could not be detected between the erythrocyte lifespan and biochemical markers of hemolysis or inflammation.

Original languageEnglish
JournalHemodialysis international. International Symposium on Home Hemodialysis
Volume25
Issue number2
Pages (from-to)198-204
Number of pages7
ISSN1492-7535
DOIs
Publication statusPublished - Apr 2021

    Research areas

  • Hemodialysis, type&#8201, 2 diabetes, erythrocyte lifespan, chromium&#8208, 51, type 2 diabetes, chromium-51

ID: 61420502